Europe and Middle East & Africa Meningitis Diagnostic Testing Market: Introduction

According to the report, the meningitis diagnostic testing market in EMEA was valued at US$ 55.95 Mn in 2020 and is projected to expand at a CAGR of 3.7% from 2021 to 2031. Awareness about meningitis, its symptoms, and medications is most important for patients. Several meningitis disease awareness programs have been initiated to increase awareness among people.

In Africa, the Meningitis Vaccine Project (MVP) was an international partnership that began in 2010 and focused on the development, testing, licensure, and widespread introduction of a conjugate vaccine with the promise of protecting millions of lives from group A meningococcal meningitis. Increase in awareness about new meningitis diagnosis test, healthcare techniques, and disease indication is projected to boost the growth of the market in EMEA during the forecast period. Moreover, surge in global healthcare expenditure led by rise in disposable income is anticipated to drive the meningitis diagnostic testing in the near future. Rise in healthcare expenditure led by surge in awareness about different healthcare programs and availability of cost-effective diagnostic methods are expected to fuel the growth of the meningitis diagnostic testing market in EMEA during the forecast period.

Lateral Flow Assay Segment to Lead Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market

In terms of product type, the meningitis diagnostic testing market in EMEA has been classified into latex agglutination tests, lateral flow assay, PCR assay, ELISA tests, culture test, and others. The lateral flow assay segment is projected to account for major share of the meningitis diagnostic testing market in EMEA during the forecast period. The growth of the segment can be attributed to low cost of lateral flow assays (US$ 2 per test in low-income countries and US$ 5 per test in high-income countries), rapid & reliable results in near-patient settings, and lack of requirement for any lab infrastructure or cold chain transport. The test is utilized to detect bacterial meningitis. Rise in prevalence of bacterial meningitis is expected to propel the segment during the forecast period.

Preference for Syndromic Full Multiplex Panel

Based on panel type, the meningitis diagnostic testing market in EMEA has been bifurcated into syndromic full multiplex panel and low plex panel. The syndromic full multiplex panel segment held major market share in 2020. Increase in use of syndromic full multiplex panel in the diagnosis of different types of meningitis is likely to augment the segment during the forecast period. Instant identification of different types of meningitis in diagnostic labs using syndromic full multiplex panels has allowed higher response time and shorter waiting time.

Easy availability of syndromic full multiplex panels and rise in use of this type of panel in meningitis diagnosis are projected to propel the syndromic full multiplex panel segment over the next few years.

Hospitals to be Major End-user

In terms of end-user, the meningitis diagnostic testing market in EMEA has been divided into hospitals, diagnostic laboratories, and others. Meningitis is a fatal disease that requires immediate care. Therefore, increase in number of hospital visits and rise in prevalence of meningitis are projected to boost the growth of the hospitals segment during the forecast period. The diagnostic centers segment held the second largest share of the market in 2020. Diagnostic centers are specially meant only for disease detection. These are well equipped with sophisticated instruments, hence people in developing and under-developed countries prefer diagnostics centers.

Europe to Lead Europe and Middle East & Africa Market Meningitis Diagnostic Testing Market

Europe dominated the meningitis diagnostic testing market in EMEA in 2020, accounting for 60.7% market share. The availability of rapid diagnostic tests, routine vaccination programs to prevent meningitis, and increase in patient awareness are projected to drive the market in Europe during the forecast period.

Middle East & Africa is a rapidly expanding market for meningitis diagnostic testing. The market in the region is anticipated to expand at a high CAGR from 2021 to 2031 due to rise in demand for meningitis diagnostic testing.

Competition Landscape

The meningitis diagnostic testing market in EMEA is fragmented due to the presence of a large number of leading players. Key players operating in the market include Thermo Fisher Scientific, Inc., Abbott Laboratories, BioFire Diagnostics, Bio-Rad Laboratories, Inc., ELITechGroup, Fast Track Diagnostics Ltd. (Siemens Healthineers), IMMY, Nanosphere (Luminex Corporation), Seegene, Inc. and Qnostics.

-Ends-

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2022

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.